Gilead to Buy Cancer Drugmaker Immunomedics in $21bn Deal
Gilead Sciences will acquire biotech company Immunomedics in a $21 billion deal that will expand Gilead’s availability of cancer treatments, the companies announced on Sunday, CNBC informs. The deal will provide Gilead access to the […]